Journal
AMERICAN JOURNAL OF ROENTGENOLOGY
Volume 208, Issue 2, Pages 290-299Publisher
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.16.17223
Keywords
breast cancer; breast MRI; breast PET; molecular breast imaging; neoadjuvant chemotherapy
Funding
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
OBJECTIVE. Neoadjuvant chemotherapy is becoming the standard of care for patients with locally advanced breast cancer. Conventional imaging modalities used for the assessment of tumor response to neoadjuvant chemotherapy rely on changes in size or morphologic characteristics and, therefore, are inherently limited. CONCLUSION. Functional imaging technologies evaluate vascular, metabolic, biochemical, and molecular changes in cancer cells and have a unique ability to detect specific biologic tumor markers, assess therapeutic targets, predict early response to neoadjuvant chemotherapy, and guide individualized cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available